Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 620,700 shares, a growth of 453.7% from the December 31st total of 112,100 shares. Approximately 21.0% of the company’s shares are sold short. Based on an average trading volume of 1,140,000 shares, the short-interest ratio is currently 0.5 days.
Clearmind Medicine Price Performance
NASDAQ:CMND traded down $0.02 during trading hours on Tuesday, reaching $1.37. 193,584 shares of the company were exchanged, compared to its average volume of 224,420. The stock has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $1.40. Clearmind Medicine has a 52-week low of $0.95 and a 52-week high of $2.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.71 and a current ratio of 1.71.
Clearmind Medicine (NASDAQ:CMND – Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter.
Clearmind Medicine Company Profile
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
See Also
- Five stocks we like better than Clearmind Medicine
- 3 Warren Buffett Stocks to Buy Now
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- What Does the Future Hold for Eli Lilly?
- How to Capture the Benefits of Dividend Increases
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.